Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On the maturity date of the Bridge Financing, the Loan Parties are obligated to make a payment equal to all unpaid principal and accrued interest. The Loan and Security Agreement also provides that all present and future indebtedness and the obligations of the Borrower to Madryn shall be secured by a priority security interest in all real and personal property collateral of the Loan Parties.
The initial drawdown under the Loan and Security Agreement occurred on April 23, 2024, when the Lenders agreed to provide the Borrower with bridge financing in the form of a term loan in the principal amount of $2,237,906.85.
The second drawdown under the Loan and Security Agreement occurred on July 26, 2024, when the Lenders agreed to provide the Borrower with a subsequent drawdown under the Loan and Security Agreement in the principal amount of $1,000,000.
On September 11, 2024, the Lenders agreed to provide the Borrower with a subsequent drawdown under the Loan and Security Agreement in the principal amount of $1,000,000 (the “September Drawdown). The September Drawdown was fully funded on September 11, 2024. The Company expects to use the proceeds of the September Drawdown, after payment of transaction expenses, for general working capital purposes.
new high not bad, might be a small rallye starting
any ideas on the debt? TIA
Venus Concept Announces Australian Regulatory Approval for Venus Bliss MAX
TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has clearance from the Therapeutic Goods Administration (TGA) in Australia to market the Venus Bliss MAX system. The Venus Bliss MAX is the Company’s flagship platform that offers a comprehensive, world-class solution for all customers’ body treatment needs and is currently available in select markets globally.
Featuring three of Venus Concept’s market leading technologies in one, the Venus Bliss MAX is a body shaping solution consisting of our proprietary (MP)2 applicator that combines Multi-Polar Radio Frequency with Pulsed Electro Magnetic Fields and advanced VariPulse™ technology for Cellulite Reduction and Skin treatments, Venus’ FlexMax EMS applicators for Muscle Conditioning and a diode laser for Fat Reduction treatments.
“We are excited to introduce to the Australian market the Venus Bliss MAX, our device that offers aesthetic clinicians an all-in-one body solution to customers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept. “The Venus Bliss Max continues to receive strong positive feedback globally from service providers of its complete body offering, and we are confident the same success will be replicated in Australia.”
VERO............................https://stockcharts.com/h-sc/ui?s=VERO&p=W&b=5&g=0&id=p86431144783
Yep a killing today. Left bagholders bagging. Trade smart greed always fails
Smart move to sell the .57’s $$$$$$
With only 6.3 mil shares outstanding,it will be very interesting how she trades once the regular trading market opens
Sold in the 1.80’s, from .57’s, b a fool not to. We’ll watch the open
VERO: Watch out for the morning 'VENUS FLY TRAP' routine, Homeboys!!!
"Alex Trebek Junior here, for the new Guess-That-GIF game show!! And here's our very first GIF!! Name all of the things, people, etc., therein beginning with the word VENUS!!"
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
VERO: Excellent point!! Which is simply yet another PERSPECTIVE upon my last post here. (He can't even SEE my posts, since he's got my on Ihub's IGNORE setting.)
VERO: Watch out for MONSTER crash after Open, as VERO's new "equity" (vs. debt) holders grab their gains --- not to mention the INSIDERS & their HomeBoys at this Firm itself!! (But CONGRATS to all who grabbed this as LOW as possible, after that news, & have already DUMPED it all.)
I read the presser
It’s an illusion
The debt doesn’t really disappear
But, you’re right
The story could have enough moxie to move the price discovery after 4am Eastern
Expect heavy volumn tomorro premarket an at the open. Swing trade here
Venus Concept Regains Compliance with Nasdaq’s Minimum Equity Requirement
TORONTO, June 06, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that on June 4, 2024, it was notified by the Nasdaq Stock Market LLC (“Nasdaq”) that the Company had regained compliance with the stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Minimum Equity Requirement”). Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor through June 4, 2025.
The Nasdaq Staff originally issued the Company a deficiency notice on May 31, 2023, citing that stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing. On May 28, 2024, the Company completed a $35 million debt-to-equity transaction. As confirmed by the Nasdaq’s notice dated June 4, 2024, this transaction served to bring the Company into compliance with the Minimum Equity Requirement.
About Venus Concept
Whoops, I did it, again
VERO: Cute nomenclature for a routine to fix flucked-up Human SKIN!!! ("VENUS"; heck, in the EU now they can call it "VENUS DE MILO!!")
finally, accumulation started,seller/debt might be done,its moving better now
Shares outstanding 67m,volume today 78m,lots of bills paid today,future looking good with many other news worthy products in pipeline
$29.5m traded today(record high),follow the money,monthly trend so far
zero borrow,no shares to short>12.83% 0.00% 0 2022-12-21 10:45:03
12.83% 0.00% 0 2022-12-21 10:30:03
12.83% 0.00% 0 2022-12-21 10:15:03
12.83% 0.00% 0 2022-12-21 10:00:03
12.83% 0.00% 0 2022-12-21 09:45:03
12.83% 0.00% 0 2022-12-21 09:30:03
12.83% 0.00% 0 2022-12-21 09:15:04
12.83% 0.00% 0 2022-12-21 09:00:03
12.83% 0.00% 0 2022-12-21 08:45:04
12.83% 0.00% 0 2022-12-21 08:30:03
12.83% 0.00% 0 2022-12-21 08:15:03
12.83% -8.51% 75000 2022-12-21 08:00:03
12.83% -8.51% 850000 2022-12-20 17:45:03
12.83% -8.51% 850000 2022-12-20 17:30:04
12.83% -8.51% 850000 2022-12-20 17:15:03
12.83% -8.51% 850000 2022-12-20 17:00:04
12.83% -8.51% 850000 2022-12-20 16:45:04
Venus Concept Receives 510(k) Clearance for Use of its AI.ME™ Next Generation Robotic Technology for Fractional Skin Resurfacing
December 21 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its AI.ME next generation robotic technology for fractional skin resurfacing.
“We are very pleased to receive the first FDA regulatory clearance for our non-surgical robotic technology platform, AI.ME, and believe it showcases Venus Concept’s ongoing investment in technology, innovation, and clinical research towards robotics applications in the field of medical aesthetics,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “AI.ME is a first-of-its-kind robotic platform offering physicians minimally-invasive treatments for high-demand procedures requiring fractional skin resurfacing. We see AI.ME as a versatile platform and we will continue to develop the platform to provide innovative solutions in various areas of medical aesthetics, starting with fractional skin resurfacing. The AI.ME technology will be critical to maximizing the synergy between our well-established medical aesthetic business and our pioneering robotics business driven by a robust R&D pipeline developed by our team in San Jose. This 510(k) clearance brings us one step closer to our goal of commercializing AI.ME in the U.S., and we look forward to introducing our first AI.ME systems with Venus Concept’s leading physician partners in 2023.”
The AI.ME robotic system utilizes an advanced visualization system, machine vision, and Artificial Intelligence algorithms to target the dermis in a pre-planned selective, and predictable manner. It uses a smart array of micro-coring hollow punches to precisely core and excise micro-skin fractions at a precise depth to remove up to 10% of skin in the treatment area, leading to collagen deposition and fractional skin resurfacing of the treated area.
“Integrating the advancements of robotics into the area of minimally-invasive aesthetic procedures is very promising,” said Girish (Gilly) Munavalli, MD, MHS, FACMS board-certified dermatologist and advisor to Venus Concept. “This new technology may become a real game-changer in the area of medical aesthetics, offering a new level of consistency, predictability, and visualization which will differentiate it from existing energy-based solutions. We had the privilege to participate in the early clinical studies of AI.ME and it is clear that the advancements that its robotic technology presents to our practice can go far beyond fractional skin resurfacing. I’m encouraged to see some true innovation in the area of minimally-invasive aesthetic treatments and I’m looking forward to seeing the technology evolve to produce consistent transformational results.”
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 16 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
Cautionary Statement Regarding Forward-Looking Statements
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001409269/000143774922026907/vero20220930_10q.htm
Is this stock going to be de-listed from Nasdaq read page 58.???
#DDAmanda Chart on: $VERO :
You can scan for these before they run.
#DDAmanda is still the best way to find #WinningStocks before they run.
Contact/Text: 760 702-2009
What the Fact (Factor) Column is:
The Factor is a proprietary indicator used for scanning in #DDAmanda.
It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).
SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.
That's significant, and many times indicates that a run in the stock is coming.
First rating to update target price today!
Marie Thibault
BTIG
4.5 Stars
target
$7.00
ranking
Buy
analystAction
Reiterated
date
14 hours ago
TDAmeritrade Inc.
Venus Concept Stock Trades Higher After Lifting FY21 Sales Outlook
11:19 am ET August 13, 2021 (Benzinga) Print
Venus Concept Inc's (NASDAQ: VERO) Q2 sales increased 52% Y/Y to $25.8 million, beating the consensus of $24.26 million.
The increase by product category was driven by a 71% increase in lease revenue, a 29% increase in systems revenue, an 86% increase in products revenue, and a 5% increase in services revenue.
The gross margin improved to 72.5% from 70.0%, primarily driven by higher sales of Venus consumables and improved revenue mix of system sales sold under our subscription program, tracing to Venus Bliss.
Operating income increased 117% Y/Y to $1.5 million compared to a loss of $(8.8) million a year ago.
EPS of $0.01 improved from a loss of $(0.39) and ahead of analyst estimate loss of $(0.12).
FY21 Guidance: Venus expects sales of $102 million - $107 million, representing a 31% - 37% Y/Y increase, better than the Wall Street estimate of $103.24 million.
Prior sales estimate were $100 million - $105 million, +28% to 35%, Y/Y.
Price Action: VERO shares are up 1.91% at $2.13 during the market session on the last check Friday.
NSTITUTIONAL OWNERSHIP CHANGES (13F FILINGS) FOR VENUS CONCEPT (NASDAQ:VERO)
Institutional Ownership Percentage: 43.04%
8/13/2021 Vanguard Group Inc. 1,011,657 $3.15M 0.0% +3.4% 1.871%
8/12/2021 Dimensional Fund Advisors LP 116,052 $0.36M 0.0% +29.8% 0.215%
8/12/2021 Essex Investment Management Co. LLC 733,425 $2.28M 0.3% +47.2% 1.356%
8/12/2021 Ergoteles LLC 107,516 $0.33M 0.0% N/A 0.199%
8/11/2021 Bank of New York Mellon Corp 36,048 $0.11M 0.0% -57.4% 0.067%
8/11/2021 Deutsche Bank AG 59,500 $0.19M 0.0% +396.7% 0.110%
8/11/2021 Susquehanna Fundamental Investments LLC 13,000 $40K 0.0% N/A 0.024%
8/3/2021 Oppenheimer & Co. Inc. 15,500 $48K 0.0% N/A 0.029%
$VERO: My bad...... $25.8MIlly in QUARTERLY REVS Confidence is Venus Williams' secret to looking and feeling her best. In this master video, watch as Venus explains all the reasons why she loves Venus Bliss™! https://t.co/37CHKiwSDd
And Venus Williams ?????????
WOW
Cheap here at $2.10 now
GO $VERO
When they double their target price, possibly the monday more than one compulsive short seller will cry a lot
Marie Thibault
BTIG
StarStarStarStarStar
target
$7.00
ranking
Buy
analystAction
Reiterated
date
2 months ago
Anthony Vendetti
Maxim Group
StarStarStarStarStar
target
$6.00
ranking
Buy
analystAction
Reiterated
date
3 months ago
Suraj Kalia
Oppenheimer
StarStarStarStarStar
target
$4.00
ranking
Buy
analystAction
Maintained
date
3 months ago
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
69
|
Created
|
01/13/20
|
Type
|
Free
|
Moderators |
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic technologies, and reach in over 60 countries and 29 direct markets. Venus Concept focuses its product sale strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa™, Venus Legacy™, Venus Velocity™, Venus Fiore™, Venus Viva™, Venus Freeze Plus™, and Venus Bliss™. Venus Concept’s hair restoration division includes NeoGraft®, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process and the ARTAS® and ARTAS iX™ Robotic Hair Restoration Systems, which harvests follicular units directly from the scalp and create recipient implant sites using proprietary algorithms.
Venus Freeze Plus™ is the easiest-to-use system with advanced safety features for non-invasive skin tightening* and wrinkle reduction. It features two applicators: DiamondPolar™ for smaller treatment areas and OctiPolar™ for larger areas. Both of these lightweight, ergonomically designed applicators are powered by our proprietary (MP)2 technology, combining Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields. Treatments are extremely comfortable with no downtime for patients and safe for all skin types. Venus Freeze Plus™ is the ideal system for anyone looking to break into the medical aesthetic industry. in the industry. In partnering with Venus Concept, aesthetic professionals worldwide gain access to never-before-seen business features such as the most comprehensive warranty program, unmatched marketing support, continuous clinical education, valuable practice enhancement programs, and more—all at no additional cost.
© Copyright 2019 Venus Concept. All rights reserved. Venus Freeze Plus™, Venus Viva™, Venus Legacy™, Venus Velocity™ and Venus Versa™ are trademarks of Venus Concept™ and may be registered in certain jurisdictions.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |